Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulbactam-durlobactam combination for Mycobacterium Abscessus Pulmonary Disease (FORMaT-EVOLVE)
NCT07485010Phase 2Not yet recruiting
- Sponsor
- The University of Queensland
- Start
- Apr 2027
- Primary completion
- Apr 2031
- Modality
- Irreversible Covalent Inhibitors
01
Overview
Phase 2, randomised, open-label trial of sulbactam + durlobactam in Mycobacterium abscessus pulmonary disease (6 arms), sponsored by The University of Queensland. Primary endpoints: Microbiological clearance of Mycobacterium abscessus (MABS) with good tolerance at Week 62, MABS clearance from respiratory sample(s) with tolerance at Week 6 and 1 more. Planned start Apr 2027; status: not yet recruiting.
02
Drugs
sulbactam + durlobactam
03
Conditions
Mycobacterium abscessus pulmonary disease
Beyond the preview
Go deeper on NCT07485010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07485010.